Inventor · disambiguated record
Stanton Mchardy
Also filed as: MCHARDY STANTON · MCHARDY STANTON F · MCHARDY STANTON FURST
23 granted patents·19 pending applications·158 citations·filing 2000–2024
94Inventor score
Top patents by PatentIndex Score
42 records- 0190US7056930B22-Azabicyclo[3.3.1]nonane derivativesPFIZER·Filed 2004·Granted Jun 6, 2006·37 cites·22 claims
- 0289US8124639B2Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitorsMCHARDY STANTON F·Filed 2010·Granted Feb 28, 2012·13 cites·3 claims
- 0389US7049335B23-azabicyclo[3.1.0]hexane derivativesPFIZER·Filed 2002·Granted May 23, 2006·40 cites·8 claims
- 0485US7241887B23-azabicyclo[3.2.1]octane derivativesPFIZER·Filed 2004·Granted Jul 10, 2007·35 cites·8 claims
- 0582US8653108B1Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitorsMCHARDY STANTON F·Filed 2012·Granted Feb 18, 2014·5 cites·13 claims
- 0680US11401243B2Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereofUNIV TEXAS·Filed 2018·Granted Aug 2, 2022·2 cites·5 claims
- 0778US8772345B2Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitorsMCHARDY STANTON F·Filed 2011·Granted Jul 8, 2014·3 cites·7 claims
- 0876USRE40838E2-azabicyclo[3.3.1]nonane derivativesPFIZER·Filed 2007·Granted Jul 7, 2009·2 cites·22 claims
- 0976US7473787B2Bicyclic [3.1.0] derivatives as glycine transporter inhibitorsPFIZER·Filed 2004·Granted Jan 6, 2009·9 cites·4 claims
- 1075US2023271926A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1174US6444679B14-phenyl-4-heteroarylpiperidine derivativesPFIZER·Filed 2000·Granted Sep 3, 2002·8 cites·9 claims
- 1269US12071409B2Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereofUNIV TEXAS·Filed 2022·Granted Aug 27, 2024·0 cites·30 claims
- 1368US11691951B2Inhibition of Olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2021·Granted Jul 4, 2023·0 cites·8 claims
- 1467US12145913B2Inhibition of Olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2021·Granted Nov 19, 2024·0 cites·6 claims
- 1565US6960609B21-diphenylmethyl-pyrazole derivatives as opioid receptor ligandsPFIZER PROD INC·Filed 2002·Granted Nov 1, 2005·4 cites·6 claims
- 1665US2025009750A1Methods of treating disorders associated with eya overexpression and mutationsUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1765US2021114991A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1864US9169220B2Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitorsSOUTHWEST RES INST·Filed 2014·Granted Oct 27, 2015·0 cites·10 claims
- 1962US12358909B2Capsazepine analogs for the treatment of cancer and other proliferative diseasesUNIV TEXAS·Filed 2019·Granted Jul 15, 2025·0 cites·9 claims
- 2056US11304916B2Methods and compositions for the treatment of Shiga ToxicosisUNIV TEXAS·Filed 2020·Granted Apr 19, 2022·0 cites·12 claims
- 2155US2024299371A1Biaryl amide and heteroaryl amides for treatment of candida albicans infectionUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2255US2022202747A1Methods and compositions for the treatment of shiga toxicosisUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2354US10457676B2Capsazepine analogs for the treatment of cancer and other proliferative diseasesUNIV TEXAS·Filed 2015·Granted Oct 29, 2019·0 cites·20 claims
- 2453US11242323B2Inhibition of OLIG2 activityCURTANA PHARMACEUTICALS INC·Filed 2017·Granted Feb 8, 2022·0 cites·15 claims
- 2553US2005043345A1Pharmaceutical composition for the prevention and treatment of addiction in a mammalPFIZER·Filed 2004·Application pending·0 cites
- 2653US2007054950A13-Azabicyclo[3.1.0]hexane derivativesPFIZER·Filed 2006·Application pending·0 cites
- 2752US2024246903A1Indanone and tetraloneketo or hydroxyl oximes as cancel therapeuticsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2852US2006229455A1Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitorsPFIZER·Filed 2006·Application pending·0 cites
- 2952US2005032837A14-Phenyl-piperidine compounds and their use as modulators of opioid receptorsPFIZER·Filed 2004·Application pending·0 cites
- 3051US2005171178A13-Azabicyclo[3.1.0]hexane derivativesPFIZER·Filed 2005·Application pending·0 cites
- 3151US2004204453A14-Phenyl-piperidine compounds and their use as modulators of opioid receptorsPFIZER·Filed 2004·Application pending·0 cites
- 3250US2022227709A1Compositions and methods for treating schistosoma infectionsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3349US2010035873A1Diaryl Compounds and Uses ThereofPFIZER·Filed 2009·Application pending·0 cites
- 3448US2018244631A1Inhibition of olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3547US11952330B2Antibiotic ammonium compounds and methods for the treatment of bacterial infectionsUNIV TEXAS·Filed 2020·Granted Apr 9, 2024·0 cites·17 claims
- 3647US11685722B2Inhibition of Olig2 activityCURTANA PHARMACEUTICALS INC·Filed 2019·Granted Jun 27, 2023·0 cites·14 claims
- 3745US2005043327A1Pharmaceutical composition for the prevention and treatment of addiction in a mammalPFIZER·Filed 2004·Application pending·0 cites
- 3844US2002077323A1Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependenciesFiled 2001·Application pending·0 cites
- 3940US7129263B2Preparation of 3-azabicyclo [3.1.0] hexane derivativesMCHARDY STANTON FURST·Filed 2004·Granted Oct 31, 2006·0 cites·11 claims
- 4038US11492331B2Redox substrates for leukocyte esteraseUNIV TEXAS·Filed 2018·Granted Nov 8, 2022·0 cites·10 claims
- 4135US2009163482A1Tetralines antagonists of the h-3 receptorMCHARDY STANTON FURST·Filed 2007·Application pending·0 cites
- 4235US2010285087A1Single phenothiazine enantiomers as agents for the prevention of bone lossUNIV TEXAS·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stanton Mchardy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →